QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Reports Q2 2018 Financial Results; Provides Business Update

Pressure BioSciences (OTCQB: PBIO) this morning provided a business update, offered limited guidance for the remainder of 2018 and reported financial results for the second quarter ended June 30, 2018. Per the update, total revenue for the second quarter was $638,800, an increase of 18% compared to $540,400 for the same period in 2017. The company attributed the increase primarily to its double-digit growth in products and services, reporting revenue totaling $618,400 for the second quarter of 2018 compared to $480,400 for the same quarter of 2017, a 29% increase. In addition, Pressure BioSciences is holding an earnings conference call at 4:30 PM ET on Wednesday, August 15, 2018. To attend the conference via telephone, dial the North American line [phone] or the international line [phone] using the verbal passcode “PBIO Second Quarter 2018 Financial Results Call.”

“We have just completed one of the most successful quarters in the history of the company. We reported our tenth consecutive quarterly increase (YoY) in products and services revenue. Total revenue was one percent away from an all-time record. Quarterly gross profit margins increased by double digits (YoY). During the quarter, operating loss decreased by $283,400 (24%), as our focus on reducing expenditures in investor and public relations, advertising, and non-essential corporate services began to pay dividends. Importantly, while we were posting revenue increases and operating expense decreases, we were also successful in completing a critical objective of converting $13.6 million of debt into equity,” Pressure BioSciences Vice President of Finance and CFO Joseph L. Damasio stated in the news release.

To view the full press release, visit http://ibn.fm/vUJC5

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com